Definition · Plain-language
Premarket Approval (PMA)
Premarket Approval (PMA) is the FDA’s most rigorous device review pathway, required for high-risk Class III medical devices and based on independent scientific evidence of safety and effectiveness.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What PMA is for
Premarket Approval is the regulatory route for the highest-risk medical devices — Class III devices, which generally support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. Because these devices cannot rely on a predicate to establish equivalence, the manufacturer must independently demonstrate, to the FDA’s satisfaction, that the device is safe and effective for its intended use. PMA is the most stringent type of device marketing application the agency requires.
The valid-scientific-evidence standard
A PMA must be supported by valid scientific evidence sufficient to provide reasonable assurance of safety and effectiveness. In practice this usually means well-controlled clinical investigations, alongside non-clinical laboratory studies and detailed manufacturing information. The FDA reviews the full application — and may convene an advisory panel of outside experts — to weigh the benefits and risks. The agency also assesses whether the manufacturing facilities and controls meet quality requirements before granting approval.
Approval and post-market duties
When the FDA is satisfied, it issues an order approving the PMA, and the device may be marketed. Because the language tracks the evidentiary standard, the FDA "approves" a PMA device, in contrast with the "clearance" of a 510(k) device. Approval can carry conditions, such as post-approval studies or specific labelling, and significant changes to an approved device generally require a PMA supplement. This higher burden reflects the greater risk these devices pose to patients.
Key facts
At a glance
- Definition: The FDA’s most stringent device marketing pathway.
- Stands for: Premarket Approval.
- Applies to: High-risk Class III medical devices.
- Standard: Valid scientific evidence of safety and effectiveness.
- Evidence: Typically includes clinical investigation data.
- FDA action: The device is "approved", not merely "cleared".
Common misconceptions
What people often get wrong
Often heard: PMA and 510(k) are interchangeable routes to market a device.
Actually: They differ in rigour and standard. PMA applies to high-risk Class III devices and requires independent evidence of safety and effectiveness; 510(k) applies mainly to Class II devices and relies on substantial equivalence to a predicate.
Often heard: A PMA never requires clinical trials.
Actually: A PMA must be supported by valid scientific evidence of safety and effectiveness, which for most Class III devices includes well-controlled clinical investigations in addition to laboratory and manufacturing data.
Often heard: Once a PMA is approved, the device can be changed freely.
Actually: Significant changes to an approved device — to design, components, manufacturing or labelling affecting safety or effectiveness — generally require a PMA supplement reviewed by the FDA before the change is marketed.
Going deeper
